Inhibition of human matriptase by eglin c variants (Q33237770)

24 July 2017

Inhibition of human matriptase by eglin c variants (English)

1 reference

24 July 2017

Marie-Eve Beaulieu

3

0 references

author name string

Antoine Désilets

series ordinal

1

1 reference

24 July 2017

Jean-Michel Longpré

series ordinal

2

1 reference

24 July 2017

Richard Leduc

series ordinal

4

1 reference

24 July 2017

language of work or name

English

0 references

publication date

20 March 2006

1 reference

24 July 2017

1 reference

24 July 2017

580

1 reference

24 July 2017

2227-2232

1 reference

24 July 2017

9

1 reference

Reverse biochemistry: use of macromolecular protease inhibitors to dissect complex biological processes and identify a membrane-type serine protease in epithelial cancer and normal tissue

24 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Matriptase/MT-SP1 is required for postnatal survival, epidermal barrier function, hair follicle development, and thymic homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Activation of hepatocyte growth factor and urokinase/plasminogen activator by matriptase, an epithelial membrane serine protease

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Cellular localization of membrane-type serine protease 1 and identification of protease-activated receptor-2 and single-chain urokinase-type plasminogen activator as substrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Inhibition of tumor invasion by genomic down-regulation of matriptase through suppression of activation of receptor-bound pro-urokinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Deregulated matriptase causes ras-independent multistage carcinogenesis and promotes ras-mediated malignant transformation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

The TMPRSS2 gene encoding transmembrane serine protease is overexpressed in a majority of prostate cancer patients: detection of mutated TMPRSS2 form in a case of aggressive disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

The transmembrane protease serine (TMPRSS3/TADG-12) D variant: a potential candidate for diagnosis and therapeutic intervention in ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Hepsin promotes prostate cancer progression and metastasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Subtilase-like pro-protein convertases: from molecular specificity to therapeutic applications

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Two engineered eglin c mutants potently and selectively inhibiting kexin or furin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Optimization of protease-inhibitor interactions by randomizing adventitious contacts

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Comparative characterization of two forms of recombinant human SPC1 secreted from Schneider 2 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

On the size of the active site in proteases. I. Papain

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Human Airway Trypsin-Like Protease Increases Mucin Gene Expression in Airway Epithelial Cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Binding of the Recombinant Proteinase Inhibitor Eglin C from LeechHzrudo Medzcznalzsto Human Leukocyte Elastase, Bovine α-Chymotrypsin and Subtilisin Carlsberg: Thermodynamic Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Changing the inhibitory specificity and function of the proteinase inhibitor eglin c by site-directed mutagenesis: functional and structural investigation

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Investigation of the solution structure of chymotrypsin inhibitor 2 using molecular dynamics: comparison to x-ray crystallographic and NMR data

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

The solution structure of eglin c based on measurements of many NOEs and coupling constants and its comparison with X‐ray structures

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Catalytic domain structures of MT-SP1/matriptase, a matrix-degrading transmembrane serine proteinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

CVS-3983, a selective matriptase inhibitor, suppresses the growth of androgen independent prostate tumor xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Structure-based approach for the discovery of bis-benzamidines as novel inhibitors of matriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Engineering of a macromolecular scaffold to develop specific protease inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

Potent and selective inhibition of membrane-type serine protease 1 by human single-chain antibodies

21 January 2018

1 reference

https://api.crossref.org/works/10.1016%2FJ.FEBSLET.2006.03.030

10.1016/J.FEBSLET.2006.03.030

21 January 2018

Identifiers

DOI

1 reference

24 July 2017

1 reference